Thank you SynBioBeta for inviting us to participate as a contributor to this panel!
This content isn’t available here
Access this content and more in the LinkedIn app
At Neochromosome, we enable biological engineering at a genome-scale. Our partners use our groundbreaking synthetic DNA and cell engineering services to investigate novel therapeutics, develop more sustainable products, and conduct pioneering scientific research. Neochromosome is uniquely suited to accelerate this work. Our first-in-class capabilities were developed to design, build, and test the world's first fully synthetic eukaryotic cells. Today, we offer our services and platform -- from highly automated synthesis of complex DNA to de novo design, synthesis, and delivery of chromosomes – to researchers around the world.
External link for Neochromosome, Inc.
3002 48th Avenue
Suite 350
New York, NY 11101, US
Thank you SynBioBeta for inviting us to participate as a contributor to this panel!
This content isn’t available here
Access this content and more in the LinkedIn app
Thank you for sharing the news GenomeWeb! HTP NGS is a core strength at Neo, and we are very happy to enable the COV-2 surveillance of the NYC DOHMH #ngs #nyc #covid19 #infectiousdiseases #sequencing #publichealth https://lnkd.in/eA3gttMD
It is a huge honor to earn this level of trust for such an important initiative. The quality of the service and the people who run it made this possible. #ngs #covid19 #rnaseq #epidemiology #infectiousdiseases #publichealth #nyc
Neochromosome, Inc. (Life Sciences, '19-20 Cohort) has been awarded a six yearlong $57M contract for Covid-19 sequencing by the NYC Department of Health and Mental Hygiene. Learn more: https://buff.ly/3TdTWpy
We've announced a collaboration with Giovanni Stracquadanio of The University of Edinburgh utilizing #artificialintelligence and #machinelearning to accelerate the development of new and more stable enzymes. Creating improved engineering processes for designer enzymes could lead to safer and more effective therapeutics, such as enzyme replacement therapy, for a broad range of genetic diseases. CEO Leslie Mitchell: “Current methods of engineering enzymes are expensive and low throughput, and most designer enzymes lack efficacy. Therefore, there is an urgent need to establish new methods of reliably creating designer enzymes on demand. This project has enabled Neochromosome to explore a new approach to enzyme engineering, demonstrating the power of our DNA Services to enable machine learning-directed protein engineering.” IBioIC Read more: https://lnkd.in/gDqTukfJ
Join Neochromosome, Inc. and Illumina for a webinar on Dec. 1 from 11 am to 12 pm ET discussing where bioengineering and genomics meet. Topics will include: -- Extraction-Free WGS from Dried Blood Spots for Low Coverage Sequencing with Megan Hogan (Neochromosome, Inc. Sequencing Lab) and Or Yaacov, MD (Center for Human Genetics and Genomics, @ NYU Grossman School of Medicine). -- Illumina Applications for the NextSeq 2000™ with @ Michael Smith Register now: https://lnkd.in/dUHuRGuz #wgs #illumina #ngs #dnasequencing #genomesequencing
Neo helps protein engineering groups accelerate therapeutic "design, build, test, learn" workflows. Our company assets were developed out of our synthetic yeast publications (spun out of the Boeke lab at NYU) . Visit booth 304 to learn about our novel yeast platforms and our rapid DNA services paired with novel genomic computational tools. #proteinengineering #syntheticbiology #antibody #antibodydiscovery #biotechnology